# Watch: Biotech Going Up Against Big Pharma

By Sciences · Published 2018-01-23 · Updated 2026-04-03 · Sciences on MarketScale
Canonical: https://www.marketscale.com/industries/sciences/watch-biotech-going-big-pharma

> As co-founder, chairman & chief executive of Ocugen, Shankar Musunuri, is looking to bring eye disease products to the patients that big pharma’s drugs have left out. The Malvern, Penn.-based company has four compounds in its pipeline at various stages of development. It’s most advanced candidate, OCU300, is gearing up for Phase III trials in…

## Key points

- As co-founder, chairman & chief executive of Ocugen, Shankar Musunuri, is looking to bring eye disease products to the patients that big pharma’s drugs have left out.
- The Malvern, Penn.-based company has four compounds in its pipeline at various stages of development.
- It’s most advanced candidate, OCU300, is gearing up for Phase III trials in…

As co-founder, chairman & chief executive of Ocugen, Shankar Musunuri, is looking to bring eye disease products to the patients that big pharma’s drugs have left out. The Malvern, Penn.-based company has four compounds in its pipeline at various stages of development. It’s most advanced candidate, OCU300, is gearing up for Phase III trials in 2018. It’s second candidate, OCU310, combines brimonidine, a drug usually designed for patients with glaucoma, and a steroid. With some of Ocugen’s products, like it’s OCU100 compound designed to delay the progression of retinitis pigmentosa, there is no other drug currently on the market – so there’s no immediate competition. “*The goal is to get something to the market to help patients as soon as possible because they don’t have anything today*,”

---
Source: MarketScale, https://www.marketscale.com/industries/sciences/watch-biotech-going-big-pharma. Published for AI indexing and citation; cite the canonical URL. Site guide for agents: https://www.marketscale.com/llms.txt